Update on ECMO for COVID-19 Weaning – V-A ECMO with Cardiogenic Shock Recombinant Activ. Factor VII

Vanderbilt University Medical Center; Department of CV Surgery: Faculty Forum

Update on ECMO for COVID-19: What have we learned?

Faculty:

J. Hoffman, MD,

Matt Warhoover, CCP,

A. Lepore, CCP

Tammy Sparacino Journal Club:

Early experience of pump-controlled retrograde trial off for weaning from veno-arterial extracorporeal membrane oxygenation (VA ECMO) in adult patients with cardiogenic shock. Pump-controlled retrograde trial off has recently been introduced as an effective method for weaning from veno-arterial extracorporeal membrane oxygenation in pediatric patients. However, studies on pump-controlled retrograde trial off in adults are still lacking. Thus, this study aimed to examine the outcomes of pump-controlled retrograde trial off for weaning from veno-arterial extracorporeal membrane oxygenation in adult patients.

John Ingram Knowledge Nuggets:

Recombinant Activated Human Factor VII